Digital therapeutics firm Voluntis has received US Food and Drug Administration (FDA) clearance to market its digital app, Oleena, enabling cancer patients to self-manage symptoms.

The software, a Class II medical device, also facilitates remote patient monitoring.

Oleena features clinical algorithms that offer real-time personalised insights and actionable recommendations for patients to manage their own symptoms.

In addition to individualised coaching, the recommendations include on-demand instructions for initiation and dosing of supportive therapies based on a patient’s treatment plan set by their care team.

Self-management is expected to help patients avoid distressing symptoms such as diarrhoea, pain, and nausea which can affect their daily functioning and lead to treatment interruptions.

Together with remote monitoring by care teams, it is intended to cut unnecessary emergency room visits and hospitalisations, improve care and clinical outcomes, and minimise cost burden for health systems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Oleena is also meant to assist patients across a variety of cancers and anti-cancer therapies such as chemotherapy, immunotherapy and targeted therapies.

Voluntis CEO Pierre Leurent said: “Beyond monitoring their symptoms, we believe that empowering patients via the digital delivery of real-time and personalised therapeutic interventions offers the opportunity for significant clinical and economic outcomes.

“We are delighted to introduce Oleena, the first prescription digital therapeutic in oncology, to transform patients’ experience throughout their cancer journey.”

Oleena is powered by the company’s software platform, Theraxium Oncology. All Voluntis’ oncology digital therapeutics are based on this platform.

Theraxium Oncology is designed to allow data analytics and remote maintenance of digital therapeutics.

In March, Roche Pharma France terminated its alliance with Voluntis for the development of a similar symptom management digital therapeutic called ZEMY for breast cancer patients.

The companies signed an agreement in October 2015 to develop and distribute ZEMY.